Core Viewpoint - The stock of Giant Bio (02367) experienced a significant decline of 15% during trading, with a current drop of 11.8%, trading at HKD 54.2, and a transaction volume of HKD 1.716 billion. This decline is linked to allegations regarding the quality of its collagen products, which have raised concerns about potential false advertising [1]. Group 1: Company Response and Actions - Huaxi Biological has officially responded to the situation involving Dr. Hao Yu, stating that after receiving his request for assistance, it collaborated with multiple third-party testing organizations to conduct tests on related products, revealing that the recombinant collagen content did not meet standards [1]. - Huaxi Biological has submitted dozens of test reports to the National Medical Products Administration, indicating a proactive approach to address the allegations [1]. Group 2: Allegations and Product Quality Issues - On May 24, beauty blogger Dr. Hao Yu released a report claiming that the actual recombinant collagen content in Giant Bio's "Collagen Stick" was only 0.0177%, significantly lower than advertised, and that a key amino acid, glycine, was "not detected," raising suspicions of false advertising [1]. - Giant Bio quickly denied these claims, asserting that its products comply with regulations and that internal testing showed results exceeding 0.1% [1]. - On June 23, Giant Bio acknowledged that its existing quality standards, testing methods, and labeling have shown limitations in certain aspects, indicating a recognition of potential issues within its product quality assurance processes [1].